Antigen-specific T cells
Tumor-infiltrating lymphocytes
Stem cells
Regulatory T cells
Content
- Antigen-specific T cells
- Tumor-infiltrating lymphocytes
- Stem cells
- Regulatory T cells
Cell manufacturing demands the highest standards of safety, precision, and reliability. The MACSQuant® Tyto® Family enables gentle cell sorting that preserves cell functionality, delivering high-quality cell products in a cartridge-based system.
In the closed cartridge and without fluidics, cells are kept sterile at all times and are never in contact with the instrument. Our MACS® GMP Tyto Consumables and MACSQuantify™ Tyto Software enable GMP compliance while streamlining your transition to regulated environments.
Since its launch in 2016, the MACSQuant Tyto Cell Sorter has been supporting numerous clinical trials worldwide.
Note: The MACSQuant Tyto Family of cell sorters and related accessory products are not sold as medical devices.
Flow cytometry–based assays are critical in cell manufacturing workflows. With our MACS GMP Tyto Consumables, the MACSQuant Tyto Cell Sorter enables seamless transition to regulated environments, offering a safe and gentle solution for cell therapy workflows.
Antigen-specific T cells
Tumor-infiltrating lymphocytes
Stem cells
Regulatory T cells
Antigen-specific T cell therapies offer immense potential for treating cancer, infectious diseases, and autoimmune disorders. Due to their unique specificity, antigen-specific T cells are diverse and rare, representing only 0.01–0.1% of the T cell pool, and therefore exceptionally challenging to detect and isolate. The MACSQuant Tyto Family enables gentle, high-purity isolation of these rare T cells, paving the way for advanced research and therapeutic breakthroughs.
Explore our data on the isolation of rare antigen-specific T cells with high purity, using the gentle and sterile cell sorting of the MACSQuant Tyto Cell Sorter in combination with our MHC multimer technology.
High-purity sorting: Our advanced microfluidics technology delivers precise, multiparameter sorting, delivering highly pure cell populations.
In this phase II clinical trial, the MACSQuant Tyto Cell Sorter was used to isolate antigen-specific CD8⁺ T cells from patient-derived peripheral blood mononuclear cells (PBMCs), following CD25⁺ regulatory T cell depletion with the CliniMACS® Plus Instrument.
Reliability: The MACSQuant Tyto Cell Sorter consistently delivered high purity and yield, providing high-quality cell products.
Effective post-sort cell expansion: The gentle microchip technology preserved cell viability and functionality in a closed, sterile environment, promoting effective post-sort cell expansion in vitro.
Tsimberidou, A.M. et al. (2023) Cancer Immunol Res. 11 (7): 925–945.
In this pioneering clinical trial, the MACSQuant Tyto Cell Sorter was used to isolate CD8⁺ T cells specific for up to four predefined peptide-HLA cancer targets. These endogenous cells were primed, expanded, and reinfused following lymphodepletion.
Target-specific T cells reached up to 78.7% of CD8⁺ cells in the patient's blood, persisted for over a year, were detected in post-treatment tumor tissue, and were associated with signs of disease stabilization in some patients. These results underscore the critical role of gentle, safe, and precise cell sorting for cell therapy workflows.
Ali Mohamed, PhD, Vice President CMC
Immatics, Houston, USA
Tumor-infiltrating lymphocytes (TILs) are tumor-reactive immune cells that naturally migrate into the tumor microenvironment. TIL therapy has shown promising results, especially in solid tumors like melanoma. Our GMP-compliant sorting workflow streamlines clinical-grade TIL manufacturing.
Watch the webinar to learn how the MACSQuant Tyto Cell Sorter is being used to achieve sterile, high-purity sorting of tumor-reactive TILs, a critical step in the development of adoptive cell therapy for the treatment of refractory metastatic melanoma.
Stem cells, like induced pluripotent stem cells (iPSCs) hold immense promise in regenerative medicine due to their unique ability to self-renew and differentiate into diverse specialized cell types. The MACSQuant Tyto Family provides gentle sorting in a closed cartridge that protects and preserves the delicate nature of stem cells.
In a groundbreaking clinical trial, now published in Nature (Sawamoto, N. et al., see below), Jun Takahashi’s team used iPSC-derived dopaminergic progenitors from HLA-matched healthy donors to treat Parkinson's disease. During the preclinical development, the team switched from a conventional droplet sorter to the MACSQuant Tyto Cell Sorter, and the impact was significant:
Improved cell viability: Gentle, sterile sorting significantly increased post-sort survival rates, resulting in higher yields of viable dopaminergic progenitors with preserved functionality.
Reduced sorting time: The MACSQuant Tyto Cell Sorter streamlined the sorting process, reducing the estimated time for cell production by one-third.
Sawamoto, N. et al. (2025) Nature 641, 971–977.
In this groundbreaking clinical trial published in Nature, Jun Takahashi’s team at CiRA (Kyoto, Japan) chose the MACSQuant Tyto Cell Sorter to gently isolate dopaminergic progenitor cells, preserving cell functionality while increasing workflow efficiency.
Regulatory T cells (Tregs) comprise only 1–4% of circulating peripheral blood mononuclear cells (PBMCs). Essential in preventing autoimmunity, their immunosuppressive role makes them a powerful tool for cell and gene therapy. However, their low abundance and phenotypic overlap with other T cell subsets present significant challenges for their application. The MACSQuant Tyto Family offers a gentle solution.
Regulatory T cells were isolated from leukapheresis products through a workflow combining automated pre-enrichment on the CliniMACS Prodigy® and high-purity sorting on the MACSQuant Tyto Cell Sorter. A sequential cell sorting approach enabled enrichment from 38% to a final purity of 98%.
Read the whole study here: